HilleVax
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 90
- Market Cap
- $96M
- Website
- http://www.hillevax.com
- Introduction
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments
• Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.
• Several companies, including Intellia Therapeutics and IGM Biosciences, are cutting a significant portion of their workforce to focus on key programs and extend cash runways.
• These workforce reductions are often accompanied by discontinuation of certain drug development programs and a shift in strategic focus towards core assets.
• The layoffs reflect a broader trend in the industry as companies adapt to evolving market dynamics and prioritize efficiency and long-term sustainability.
Moderna's mRNA Norovirus Vaccine Enters Phase 3 Trial
• Moderna's mRNA-1403 norovirus vaccine has entered a pivotal Phase 3 trial, evaluating its efficacy, safety, and immunogenicity in adults.
• The global trial, named Nova 301, aims to enroll approximately 25,000 participants, focusing on adults aged 60 years and older.
• mRNA-1403 is a trivalent vaccine designed to protect against multiple norovirus genotypes, addressing a significant public health concern.
• Interim Phase 1/2 data showed promising safety and immunogenicity, supporting the Phase 3 trial's initiation and potential for regulatory submission in 2026.
© Copyright 2025. All Rights Reserved by MedPath